Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two ways to quiet a racing heart: trial pits hybrid ablation against standard catheter treatment

NCT ID NCT05723536

Disease control Sponsor: Hospital Clinic of Barcelona Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers compare two procedures for people with persistent atrial fibrillation that has not responded to at least one antiarrhythmic drug. One group receives standard catheter ablation, which burns or freezes small areas inside the heart. The other receives a hybrid procedure that combines keyhole surgery and a catheter to isolate more of the left atrium in a single session. The trial tracks heart rhythm over a year using an implanted monitor and uses MRI and echocardiography to see how heart structure affects success.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Partial left atrial isolation, a hybrid surgical and catheter procedure that electrically isolates parts of the left atrium
What this could lead to
If it works, this hybrid approach could give people with persistent atrial fibrillation a better shot at staying in normal rhythm than standard catheter ablation alone.
What could go wrong
The hybrid procedure is more invasive than catheter ablation and may carry extra risks. This is a small, single-center trial, so results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients between the ages of 18 and 75, both inclusive, at the time of the consent date. 2. Patients with persistent atrial fibrillation refractory to at least one antiarrhythmic drug (Class I or III). 3. Signature of written informed consent. Exclusion Criteria: 1. Continuous Persistent atrial fibrillation of more than 4 years. 2. Moderate to severe valvular heart disease. 3. Severe atrial dilatation (left appendage AP diameter \> 55 mm or \> 50ml/m2). 4. Patients requiring concomitant cardiac surgery or with previous cardiac surgery. 5. Left ventricular ejection fraction \<40%. 6. History of pericarditis. 7. Previous stroke. 8. Presence of active infection or sepsis, esophageal ulcer stricture and/or esophageal varices. 9. Patients with renal dysfunction defined as GFR less than or equal to 40 ml/min/m2. 10. Contraindication for chronic anticoagulation. 11. Patients who have undergone prior left atrial catheter ablation for atrial fibrillation or who are receiving treatment for ventricular arrhythmia. 12. Patients with severe chronic obstructive pulmonary disease considered GOLD III. 13. Patients with active neoproliferative disease or other concomitant disease where the medical team considers that ablation places the patient at unacceptable risk. 14. Pregnant, lactating women. 15. Patients who have previously presented allergic reactions to gadolinium. 16. Patients with claustrophobia that makes it impossible to perform nuclear magnetic resonance. 17. Persistent AF \< 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrythmia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation cardiac rhythm disease persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arrythmia Atrial fibrillation Persistent atrial fibrillation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Clínic de Barcelona

    RECRUITING

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.